News Releases

Press Releases

  • 11/10/16 4:00 pm EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM), a highly differentiated, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17, 2016, at 2:00 p.m. Eastern Time. Dr. Aklog will provide a corporate overview including recent developments, discuss the company’s innovative business model and reviewmore...
  • 11/4/16 1:25 pm EDT

    Agreement provides PAVmed with license to develop and commercialize antibiotic-eluting resorbable ear tube devices expected to benefit up to one million children per year

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced that it has signed a definitive licensing agreement with a group of leading academic institutions, including Tufts University and two Harvard Medical School teaching hospitals – Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital. The agreement provides PAVmed with an exclusive worldwide license to develop andmore...
  • 10/28/16 7:00 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced that the company has filed a registration statement on Form S-1 with the Securities and Exchange Commission to register the issuance of 1,060,000 shares of common stock underlying the IPO warrants. The company completed its IPO on April 28, 2016. The IPO warrants are exercisable at a price of $5.00 per share commencingmore...
  • 9/20/16 7:00 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM), a highly differentiated, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, at 3:30 p.m. ET in New York City. Dr. Aklog will provide a corporate overview, discuss the company’s innovative business model and review PAVmed’s lead products. Themore...
  • 9/7/16 4:05 pm EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM), a highly differentiated, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016, at 5:05 pm ET taking place at the Lotte New York Palace Hotel in New York City. Dr. Aklog will provide a corporate overview, discuss the company’smore...
  • 8/16/16 7:00 am EDT

    - Conference Call to be Held August 17 th -

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM) (“PAVmed” or the “Company”), a highly-differentiated multi-product medical device company, today announced financial results for the second quarter ended June 30, 2016 and provided a business update. “We have made solid progress in executing on our milestones and advancing our growth strategy, during the quarter and recent weeks,” said Dr. Lishan Aklog, Chairman and Chief Executive Officer of PAVmed. “Ofmore...
  • 8/12/16 12:39 pm EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM), a highly differentiated, multi-product medical device company, today announced that the Company will host a conference call on August 17, 2016 at 4:30 p.m. Eastern time during which PAVmed’s Chairman and CEO, Dr. Lishan Aklog, will provide a business update and discuss near term milestones and growth strategy. To access the conference call, U.S.-based listeners should dial (844) 666-7591 and internationalmore...
  • 7/26/16 3:10 pm EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVMU), a highly differentiated, multi-product medical device company, announced today that Jan David Wald, Ph.D., Senior Research Analyst at The Benchmark Company, has initiated research coverage on PAVmed. For more information on this report please contact John Borer at investmentbanking@benchmarkcompany.com. About PAVmed PAVmed Inc. (Nasdaq: PAVMU) is a highly differentiated, multi-productmore...
  • 7/26/16 7:00 am EDT

    -Common Stock (Nasdaq:PAVM) and Warrants (Nasdaq:PAVMW) will trade separately-

    -Units (Nasdaq:PAVMU) will cease trading upon separation-

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVMU), a highly differentiated, multi-product medical device company, announced today that the common stock and warrants underlying the units sold in its initial public offering would commence separate trading on or about July 27, 2016. The common stock and warrants will be listed on the Nasdaq Capital Market (“Nasdaq”) under the symbols PAVM and PAVMW, respectively. The units, which are currently trading on Nasdaq under themore...
  • 7/14/16 7:00 am EDT

    -Commercialization of PortIO™ implantable vascular access device anticipated in 2017-

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVMU), a highly differentiated, multi-product medical device company, announced today that it has set a Q4 2016 timeline for FDA 510(k) submission of its first product, the PortIO™ implantable vascular access device. PortIO has entered verification and validation testing, the final phase of pre-submission testing. Lishan Aklog, M.D., Chairman and CEO of PAVmed, said “We are excited about our timeline for submittingmore...

SEC Filings

Click Here to view PAVMed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation